Copenhagen, Denmark; October 20, 2003 – Genmab A/S (CSE: GEN) will hold an  Extraordinary General Meeting on Tuesday November 11, 2003 at 4:00 pm at the Scandic Hotel Copenhagen, Vester Søgade 6, 1601 Copenhagen V, Denmark.

The purpose of the Extraordinary General Meeting and sole item on the agenda is the proposed election of a new member of the Board of Directors.

The Board of Directors proposes the election of Dr. Anders Gersel Pedersen, who if elected, will bring the number of members of Genmab A/S’s Board of Directors to a total of six.

Dr. Pedersen (age 52) is Senior Vice President, Development at H. Lundbeck A/S, Denmark. Following his degree in medicine and Research Fellow positions at Copenhagen hospitals, Dr. Pedersen worked for Eli Lilly for eleven years; ten of these as a director of world-wide clinical research in oncology, before joining Lundbeck in 2000. At Lundbeck Dr. Pedersen is responsible for the development of the product pipeline including the clinical research. He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine and serves on the board of TopoTarget A/S. Dr. Pedersen received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a BSc in Business Administration from the Copenhagen Business School.

Admission card: Any shareholder is entitled to attend the Extraordinary General Meeting after having submitted a request for an admission card no later than November 6, 2003.

Any shareholder, to whom an admission card already has been issued, who is unable to attend the Extraordinary General Meeting is kindly asked to notify the Company no later than November 6, 2003